Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Finished Goods (2022 - 2025)

Historic Finished Goods for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $10.3 million.

  • Axsome Therapeutics' Finished Goods rose 1728.24% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year increase of 1728.24%. This contributed to the annual value of $9.0 million for FY2024, which is 681.32% down from last year.
  • Per Axsome Therapeutics' latest filing, its Finished Goods stood at $10.3 million for Q3 2025, which was up 1728.24% from $9.5 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Finished Goods ranged from a high of $10.3 million in Q3 2025 and a low of $1.6 million during Q4 2022
  • For the 4-year period, Axsome Therapeutics' Finished Goods averaged around $7.9 million, with its median value being $8.8 million (2024).
  • In the last 5 years, Axsome Therapeutics' Finished Goods surged by 50647.8% in 2023 and then crashed by 1199.92% in 2025.
  • Over the past 4 years, Axsome Therapeutics' Finished Goods (Quarter) stood at $1.6 million in 2022, then soared by 506.48% to $9.6 million in 2023, then fell by 6.81% to $9.0 million in 2024, then increased by 15.17% to $10.3 million in 2025.
  • Its last three reported values are $10.3 million in Q3 2025, $9.5 million for Q2 2025, and $9.0 million during Q1 2025.